API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BIAL has established a new affiliate in the U.S BIAL Biotech Investments Inc. Additionally, BIAL has acquired worldwide rights of LTI-291 and all the Parkinson’s disease research programs of Lysosomal Therapeutics and taken on the entire R&D team.
Lead Product(s): LTI-291
Therapeutic Area: Neurology Product Name: BIA 28-6156
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: BIAL
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 01, 2020